FDA Says Amylin Hid Diabetes Drug Safety Data
Amylin Pharmaceuticals Inc. withheld heart safety data from regulators while seeking approval for its extended-release diabetes drug Bydureon, which the U.S. Food and Drug Administration eventually approved in January, according to...To view the full article, register now.
Already a subscriber? Click here to view full article